Retrospective review highlights the prognosis of immune-mediated necrotizing myopathy in patients with anti-HMGCR antibodies, suggesting early treatment may improve outcomes.
Key Points
Prolonged treatment delay leads to poorer prognosis in patients with anti-HMGCR-positive immune-mediated necrotizing myopathy.
Initial creatine kinase levels showed severe elevations, ranging from 1438 to over 13,000 IU/L in patients diagnosed with myopathy.
Treatment regimens included multiple immunosuppressive agents, with follow-up showing changes in creatine kinase levels over 180 days.
Correlation found between delayed symptom treatment and longer time required for obtaining first remission in myopathy patients.